which Teva predicts will bring in $2.5 billion in sales in 2027, fuelled by growth of a new once-daily formulation. That’s a sizeable increase on Teva’s projections of around $1.2 billion for ...

Teva has agreed to pay a whopping $1.2 billion ... when the drug was pulling in $1 billion in sales. According to the FTC, Cephalon paid the companies to drop patent challenges and delay the ...

The general mood among these heavyweight investors is divided, with 44% leaning bullish and 33% bearish. Among these notable options, 5 are puts, totaling $256,004, and 4 are calls, amounting to ...

Cox likened the new campaign to a reset for Teva, which has seen its sales slide over the past couple of years amid increased competition in the outdoor market. In the third quarter, Teva brand net ...

A leader in CNS specialty medicine sales in the United States and in the top five globally, Teva Pharmaceuticals is actively looking to expand its CNS portfolio further.

while forecasting that the global sales of Selarsdi could potentially reach $390 million by 2028. Shares of Teva Pharma marginally down 1% in early morning trading, while Alvotech's saw a 5% increase.